Abcellera Biologics Inc ABCL

$11.49 -0.13 (-1.12%)

Valuation

Market cap
3,795,301,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
2,677,600
Avg volume
4,299,200
Day's range
$11.06 – $11.83
Shares out
326,618,000
Stochastic %K
33%
Beta
1.59
Analysts
Strong Buy
Price target
$17.92

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

PaloPB Nov 14, 9:23 AM
$ABCL the CEO trusts the company's future
0 replies
SuperGreenToday Nov 14, 4:06 AM
$ABCL Share Price: $11.49 Contract Selected: Apr 16, 2027 $10 Calls Buy Zone: $2.21 – $2.73 Target Zone: $4.17 – $5.10 Potential Upside: 78% ROI Time to Expiration: 152 Days | Updates via https://fxcapta.com/stockinfo/
0 replies
SCSyndrome Nov 14, 12:23 AM
$ABCL This is the only stock that holds. Fuck this market. Monday I am selling everything and averaging up big time with $ABCL Fuck it. It’s the only one that holds.
1 replies
BioRich Nov 13, 9:26 PM
$ACAD and $CADL, Nice 20+% trades. Still hold a profitable core for $CADL but rolling these swings into cores for $SMMT and $ABCL. Already top 5 holdings (#2 and #4, respectively). Will be fun to watch how this rotation plays out. Follow/Subscribe for more suggestions and perspective. Would love to hear yours too. That's how we find these gems and learn. Let's make some (more) money. Cheers! $XBI
0 replies
CoffeeRocks Nov 13, 8:41 PM
$LPCN $SLS $IOVA $ABCL $BCTX LOCN catching a BiD????? 1.5$S to ?????
0 replies
erpy Nov 13, 8:11 PM
$ABCL Ok ok ill add. Lets go. I like green!
0 replies
erpy Nov 13, 7:33 PM
$ABCL Slow and steady ok. Pace wins the Race. 3 new molecules, a potential superior hot flash drug in todays market over 800M cash, insiders loading, new conferences galore. Got one word YUMMY
0 replies
Odoji Nov 13, 7:28 PM
$ABCL 💉
0 replies